Accumulated CV data from SGLT2i outcomes trials

The dawn of CV risk reduction in type 2 diabetes: 5 years of SGLT2i CV outcome trials.

Summary of clinical and scientific topics discussed at EASD 2020 congress

The most important clinical and scientific findigs presented at the EASD 2020 Virtual Congress are summed up by Professor Stefano Del Prato.

Remission of type 2 diabetes with return of insulin secretory function restores normal pancreas morphology

The size and shape of the pancreas can be restored in individuals with type 2 diabetes who achieve remission as a result of an intensive weight loss and weight loss maintenance programme, shows a new analysis from the landmark DiRECT trial.

Effects of empagliflozin on physical activity and compensatory appetite responses in people with type 2 diabetes: the SEESAW trial

https://www.easd.org/virtualmeeting/home.html#!resources/effects-of-empagliflozin-diet-or-both-on-physical-activity-and-sedentary-behaviour-in-people-with-type-2-diabetes-analyses-from-the-seesaw-trial-33e5cd8a-0212-4173-ab31-02bd789ec795